Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review

• Published in: BMC gastroenterology 2021-07, Vol.21 (1), p.1-279, Article 279
• Main Authors: El-Alali, Emran A, Abukhiran, Ibrahim M, Alhmoud, Tarik Z
• Format: Article
• Language: English
• Subjects: Abdomen; Allergies; Antibiotics; Antihistamines; Biopsy; Case Report; Case reports; Case studies; Cholecystectomy; Clinical trials; Cysts; Diarrhea; Drug therapy; Eosinophilia; Eosinophilic gastroenteritis; Gastroenteritis; Gastroenterology; Gastrointestinal diseases; Gastrointestinal tract; Glucocorticoids; Hospitalization; Hospitals; Immunoglobulin E; Infiltration; Inflammation; Inflammatory bowel disease; Interleukin 4; Interleukin 5; Laboratories; Leukocytes (eosinophilic); Leukotriene antagonist; Literature reviews; Medical imaging; Monoclonal antibodies; Montelukast; Nausea; Pain; Pancreatitis; Patients; Remission; Small intestine; Steroid hormones; Suplatast tosilate; Vomiting
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-021-01854-x

Background Eosinophilic gastrointestinal disorders, also known as eosinophilic gastroenteritis, are rare inflammatory conditions characterized by eosinophilic infiltration of different parts of the gastrointestinal tract, along with peripheral eosinophilia in most cases. Other known causes for gut eosinophilic infiltration must be excluded to confirm the diagnosis of eosinophilic gastroenteritis. Symptoms of the disorder depend on the affected gastrointestinal tract segment and depth of involvement. Treatment includes systemic glucocorticoids and/or dietary therapy with an empiric elimination diet. Second line therapies include the leukotriene receptor antagonist montelukast, and other anti-allergy drugs such as mast cell stabilizers (including cromolyn and the H1-antihistamine ketotifen), suplatast tosilate which is a selective Th-2 cytokines (IL-4 and IL-5) inhibitor, and the monoclonal anti-IgE antibody omalizumab. We report a case of eosinophilic gastroenteritis who was successfully treated and achieved remission with montelukast as an initial monotherapy. Upon extensive literature review, this represents the second reported adult case of eosinophilic gastroenteritis who responds to montelukast alone as a first line therapy. Case presentation A 49-year-old female presented with recurrent abdominal pain, vomiting, diarrhea and unexplained eosinophilia. She was diagnosed with eosinophilic gastroenteritis and was successfully treated with montelukast monotherapy. After 7 days of therapy, the patient responded well and had complete resolution of her gastrointestinal symptoms and peripheral eosinophilia. Patient remained in remission on follow-up after 12 months. We reviewed the literature for leukotriene antagonist use in the treatment of eosinophilic gastroenteritis and included the cases treated with the leukotriene antagonist montelukast as an initial therapy or as a second line therapy for refractory disease. Conclusion Montelukast may be an effective treatment for eosinophilic gastroenteritis, either alone or in combination with systemic steroids or ketotifen. Our patient is the second reported adult case of eosinophilic gastroenteritis who responded to montelukast alone as a first line therapy. Further studies and clinical trials are required to confirm efficacy compared to standard therapy. Keywords: Montelukast, Eosinophilic gastroenteritis, Leukotriene antagonist, Case report